Combing hiPSCs with CRISPR/Cas9

 
GUANGZHOU, China - Jan. 6, 2020 - PRLog -- The past decade has seen the birth of two incredibly useful biological tools. The first is human-induced pluripotent stem cells (iPSCs), which can, in turn, be coaxed to become nearly any cell type. The second tool is the CRISPR/Cas9 system, which allows easy and precise editing of any region of the genome. The combination of hiPSCs and CRISPR/Cas9 genome editing provides an ability to repair putative causative alleles in patient lines, or introduce disease alleles into a healthy "WT" cell line.

  Mutations in the genes PARK2 (parkin) cause autosomal recessive familial Parkinson's disease. In this study, human iPSCs with PARK2 knockout introduced by genome editing have enabled investigations of parkin dysfunction in human dopaminergic neurons in vitro. This research identified and quantified more than half of all reported mitochondrial proteins and determined large numbers of dysregulated proteins in PARK2 KO neurons compared to healthy isogenic controls. Structural and functional analyses revealed an increase in mitochondrial area and the presence of elongated mitochondria as well as impaired glycolysis and lactate-supported respiration, leading to impaired cell survival in PARK2 KO neurons. This adds valuable insight into the effect of parkin dysfunction in human neurons and provides knowledge of disease-related pathways that can potentially be targeted for therapeutic intervention.

  Develop a genome modified iPSC with Ubigene today! Ubigene developed CRISPR-UTM (based on CRISPR/Cas9 technology) which is more efficient than general CRISPR/Cas9 in double-strand breaking, and CRISPR-UTM can greatly improve the efficiency of homologous recombination.
      https://www.ubigene.us/

  Now we are having a New Year Sales! Start your year off right by working with us!
      https://www.ubigene.us/activity/service/2713.html

  Reference:
      Bogetofte, Helle, et al. "PARK2 mutation causes metabolic disturbances and impaired survival of human iPSC-derived neurons." Frontiers in cellular neuroscience 13 (2019): 297.

Contact
Jin Xu
***@ubigene.com
+86-153 6067 3248
End
Email:***@ubigene.com
Posted By:***@ubigene.com Email Verified
Tags:Knockout cell line
Industry:Biotech
Location:Guangzhou - Guangdong - China
Subject:Events
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Ubigene Biosciences News
Trending
Most Viewed
Daily News

Most Viewed
Daily News
PTC News

Jan 06, 2020 News



Like PRLog?
9K2K1K
Click to Share